Document Detail


Sarcolemmal and mitochondrial adenosine triphosphate- dependent potassium channels: mechanism of desflurane-induced cardioprotection.
MedLine Citation:
PMID:  10839925     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Volatile anesthetic-induced preconditioning is mediated by adenosine triphosphate-dependent potassium (KATP) channels; however, the subcellular location of these channels is unknown. The authors tested the hypothesis that desflurane reduces experimental myocardial infarct size by activation of specific sarcolemmal and mitochondrial KATP channels. METHODS: Barbiturate-anesthetized dogs (n = 88) were acutely instrumented for measurement of aortic and left ventricular pressures. All dogs were subjected to a 60-min left anterior descending coronary artery occlusion followed by 3-h reperfusion. In four separate groups, dogs received vehicle (0.9% saline) or the nonselective KATP channel antagonist glyburide (0.1 mg/kg intravenously) in the presence or absence of 1 minimum alveolar concentration desflurane. In four additional groups, dogs received 45-min intracoronary infusions of the selective sarcolemmal (HMR 1098; 1 microg. kg-1. min-1) or mitochondrial (5-hydroxydecanoate [5-HD]; 150 microg. kg-1. min-1) KATP channel antagonists in the presence or absence of desflurane. Myocardial perfusion and infarct size were measured with radioactive microspheres and triphenyltetrazolium staining, respectively. RESULTS: Desflurane significantly (P < 0.05) decreased infarct size to 10 +/- 2% (mean +/- SEM) of the area at risk as compared with control experiments (25 +/- 3% of area at risk). This beneficial effect of desflurane was abolished by glyburide (25 +/- 2% of area at risk). Glyburide (24 +/- 2%), HMR 1098 (21 +/- 4%), and 5-HD (24 +/- 2% of area at risk) alone had no effects on myocardial infarct size. HMR 1098 and 5-HD abolished the protective effects of desflurane (19 +/- 3% and 22 +/- 2% of area at risk, respectively). CONCLUSION: Desflurane reduces myocardial infarct size in vivo, and the results further suggest that both sarcolemmal and mitochondrial KATP channels could be involved.
Authors:
W G Toller; E R Gross; J R Kersten; P S Pagel; G J Gross; D C Warltier
Related Documents :
9714095 - Nitric oxide synthase is the mediator of late preconditioning against myocardial infarc...
11869855 - Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine tri...
7736505 - Inhibition of sodium-hydrogen exchange reduces infarct size in the isolated rat heart--...
12383585 - The role of serotonin in ischemic cellular damage and the infarct size-reducing effect ...
1529945 - Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or b...
8606505 - Vascular occlusion produced over 24 hours increases spinal cord tolerance to occlusion.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Anesthesiology     Volume:  92     ISSN:  0003-3022     ISO Abbreviation:  Anesthesiology     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-07-11     Completed Date:  2000-07-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1300217     Medline TA:  Anesthesiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1731-9     Citation Subset:  AIM; IM    
Affiliation:
Departments of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Triphosphate / metabolism,  physiology*
Anesthetics, Inhalation / antagonists & inhibitors,  pharmacology*
Animals
Benzamides / pharmacology
Decanoic Acids / pharmacology
Dogs
Glyburide / pharmacology
Hemodynamics / drug effects
Hydroxy Acids / pharmacology
Hypoglycemic Agents / pharmacology
Ischemic Preconditioning, Myocardial
Isoflurane / analogs & derivatives*,  antagonists & inhibitors,  pharmacology
Mitochondria / metabolism*
Myocardial Infarction / pathology,  prevention & control
Myocardium / pathology
Potassium Channel Blockers
Potassium Channels / agonists,  metabolism*
Regional Blood Flow
Sarcolemma / metabolism*
Grant Support
ID/Acronym/Agency:
HL03690/HL/NHLBI NIH HHS; HL54280/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Anesthetics, Inhalation; 0/Benzamides; 0/Decanoic Acids; 0/HMR 1098; 0/Hydroxy Acids; 0/Hypoglycemic Agents; 0/Potassium Channel Blockers; 0/Potassium Channels; 10238-21-8/Glyburide; 26675-46-7/Isoflurane; 56-65-5/Adenosine Triphosphate; 57041-67-5/desflurane; 624-00-0/5-hydroxydecanoic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Volatile anesthetics activate the human tandem pore domain baseline K+ channel KCNK5.
Next Document:  The mechanical antihyperalgesic effect of intrathecally administered MPV-2426, a novel alpha2 -adren...